title: Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection.
abstract: BACKGROUND
  Chronic steroid use after cardiac transplantation (CTX) is accompanied by co-morbidities that are dependent on length of exposure.
  
  
  METHODS
  A retrospective review of all CTX without induction therapy from 1999-2004. After 2001, an aggressive strategy of steroid weaning was introduced.
  
  
  RESULTS
  A total of 165 patients underwent CTX, 82 from 1999-2001 (group 1) and 83 from 2002-2004 (group 2). There were no significant differences in recipient or donor characteristics between group 1 and group 2. The baseline calcineurin was cyclosporine in 41% and 5% (p < 0.0001) and tacrolimus in 59% and 95% (p < 0.0001), respectively. The mean duration of steroid use was 1023 d in group 1 and 383 d in group 2 (p < 0.0001). The overall incidence of any > or =ISHLT grade 3A rejection per year after CTX for group 1 vs. group 2 was as follows: year 1: 40% vs. 49% (p = NS) and year 2: 7.4% vs. 9.2% (p = NS).
  
  
  CONCLUSIONS
  Steroid withdrawal by one yr after CTX using a contemporary immunosuppressive regimen is possible in most patients. In comparison with a slower steroid wean, a faster wean is not associated with an excess of significant rejection in the first two yr post CTX.
authors.affiliation: Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA, USA. teutebergjj@upmc.edu
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Teuteberg
authors.forename: Michael
authors.initials: M
authors.lastname: Shullo
authors.forename: Rachelle
authors.initials: R
authors.lastname: Zomak
authors.forename: Dennis
authors.initials: D
authors.lastname: McNamara
authors.forename: Kenneth
authors.initials: K
authors.lastname: McCurry
authors.forename: Robert L
authors.initials: RL
authors.lastname: Kormos
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage*; D011446:Prospective Studies; D012189:Retrospective Studies; D014886:Weaning; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011241:Prednisone; D008775:Methylprednisolone